Maze Therapeutics, Inc. (Nasdaq: MAZE) — As of 2026-10-28

Recent catalysts (last ~1–3 months)

Q2 2026 financials and pipeline update (Aug 11, 2026). The company reported $494.9 million in cash, cash equivalents, and marketable securities, with a cash runway into 2029, and reported $20.0 million in license revenue (a milestone under the exclusive Shionogi license for MZE001) against a Q2 net loss of $44.7 million ($0.76/share) and R&D expenses of $34.9 million [8][9]. Management reaffirmed Phase 2 HORIZON enrollment for MZE829 is on track and that the Phase 2 CIPheR trial for MZE782 in PKU has been initiated, with topline data expected in 2027 and a MZE782 CKD trial targeted for H1 2027 [7][8].